<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2022-28-4-464-476</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-2244</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Ведение пациентов с артериальной гипертензией, ишемической болезнью сердца и хронической сердечной недостаточностью в период пандемии COVID-19 в условиях первичной врачебной медико-санитарной помощи</article-title><trans-title-group xml:lang="en"><trans-title>Management of patients with hypertension, coronary heart disease and chronic heart failure during the COVID-19 pandemic in the primary care setting</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8169-7812</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Конради</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Konradi</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Конради Александра Олеговна — доктор медицинских наук, профессор, академик РАН, заведующая кафедрой организации, управления и экономики здравоохранения Института медицинского образования, заместитель генерального директора по научной работе НМИЦ им. В.А. Алмазова Минздрава России.</p><p>ул. Аккуратова, д. 2, Санкт-Петербург, 197341.</p></bio><bio xml:lang="en"><p>Aleksandra O. Konradi - MD, PhD, DSc, Professor, Academician of the Russian Academy of Sciences, Head, Department of Organization, Management and Economics of Healthcare, Institute of Medical Education, Deputy Director General on Research, Almazov National Medical Research Center.</p><p>2 Akkuratov street, St Petersburg, 197341.</p></bio><email xlink:type="simple">konradi@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Драпкина Оксана Михайловна — доктор медицинских наук, профессор, академик РАН, Президент Российского общества профилактики неинфекционных заболеваний, главный внештатный специалист по терапии и общей врачебной практике Минздрава России, директор НМИЦ ТПМ Минздрава России.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Oksana M. Drapkina - MD, PhD, DSc, Professor, Academician of the Russian Academy of Sciences, President, the Russian Society for the Prevention of Non-Communicable Diseases, Chief Freelance Specialist in Therapy and General Medical Practice of the Ministry of Health of the Russian Federation, Director, National Medical Research Center for Therapy and Preventive Medicine.</p><p>Moscow.</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5981-1754</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Недогода</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nedogoda</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Недогода Сергей Владимирович — доктор медицинских наук, профессор, заведующий кафедрой внутренних болезней Института непрерывного медицинского и фармацевтического образования ВолгГМУ Минздрава России.</p><p>Волгоград.</p></bio><bio xml:lang="en"><p>Sergey V. Nedogoda - MD, PhD, DSc, Professor, Head, Department of Internal Diseases, Institute of Continuing Medical and Pharmaceutical Education, Volgograd State Medical University.</p><p>Volgograd.</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6645-2515</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Арутюнов</surname><given-names>Г. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Arutyunov</surname><given-names>G. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Арутюнов Григорий Павлович — доктор медицинских наук, профессор, член-корреспондент РАН, президент Евразийской ассоциации терапевтов, заведующий кафедрой пропедевтики внутренних болезней РНИМУ им. Н.И. Пирогова Минздрава России.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Grigory P. Arutyunov - MD, PhD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, President, the Eurasian Association of Therapists, Head, Department of Propaedeutics of Internal Diseases, Pirogov Russian National Research Medical University.</p><p>Moscow.</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1480-0458</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карпов</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Karpov</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карпов Юрий Александрович — доктор медицинских наук, профессор, руководитель отдела ангиологии ИКК им. А.Л. Мясникова НИЦК Минздрава России.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Yuri A. Karpov - MD, Ph D. DSc, Professor, Head, Angiology Department, Institute of Clinical Cardiology named after A.L. Myasnikov, Research Center of Cardiology.</p><p>Moscow.</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1126-4282</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кобалава</surname><given-names>Ж. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kobalava</surname><given-names>Zh. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кобалава Жанна Давидовна — доктор медицинских наук, профессор, член-корреспондент РАН, заведующая кафедрой внутренних болезней и клинической фармакологии медицинского факультета РУДН.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Zhanna D. Kobalava - MD, Ph D. DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Head, Department of Internal Diseases and Clinical Pharmacology, Faculty of Medicine, Peoples' Friendship University of Russia.</p><p>Moscow.</p></bio><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8160-5612</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орлова</surname><given-names>Я. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Orlova</surname><given-names>Ya. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Орлова Яна Артуровна — доктор медицинских наук, заведующая отделом возраст-ассоциированных заболеваний МНОЦ МГУ им. М.В. Ломоносова.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Yana A. Orlova - MD, Ph D. DSc, Head, Department of Age-Associated Diseases, Medical Scientific and Educational Center, Lomonosov Moscow State University.</p><p>Moscow.</p></bio><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4496-3680</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сычев</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sychev</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сычев Дмитрий Александрович — доктор медицинских наук, профессор, член-корреспондент РАН, заведующий кафедрой клинической фармакологии и терапии, ректор РМАНПО Минздрава России.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Dmitry A. Sychev - MD, Ph D. DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Head, Department of Clinical Pharmacology and Therapy, Rector, the Russian Medical Academy of Continuing Professional Education.</p><p>Moscow.</p></bio><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6348-6867</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зырянов</surname><given-names>С. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Zyryanov</surname><given-names>S. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зырянов Сергей Кенсаринович — доктор медицинских наук, профессор, заместитель главного врача по терапии ГБУЗ ГКБ № 24 ДЗ г. Москвы.</p><p>Москва.</p></bio><bio xml:lang="en"><p>Sergey K. Zyryanov - MD, Ph D. DSc, Professor, Deputy Chief Physician for Therapy, City Clinical Hospital No. 24.</p><p>Moscow.</p></bio><xref ref-type="aff" rid="aff-9"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр имени В.А. Алмазова Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр терапии и профилактической медицины Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Волгоградский государственный медицинский университет Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н.И. Пирогова Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Институт клинической кардиологии имени А.Л. Мясникова Научно-исследовательского центра кардиологии Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Clinical Cardiology named after A.L. Myasnikov of the Research Center of Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>Российский университет дружбы народов</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Peoples' Friendship University of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>Медицинский научно-образовательный центр Московского государственного  университета имени М.В. Ломоносова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Medical Scientific and Educational Center of the Lomonosov Moscow State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-8"><aff xml:lang="ru"><institution>Российская медицинская академия непрерывного профессионального образования Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuing Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-9"><aff xml:lang="ru"><institution>Городская клиническая больница № 24 Департамента здравоохранения г. Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital No. 24</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>25</day><month>08</month><year>2022</year></pub-date><volume>28</volume><issue>4</issue><fpage>464</fpage><lpage>476</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Конради А.О., Драпкина О.М., Недогода С.В., Арутюнов Г.П., Карпов Ю.А., Кобалава Ж.Д., Орлова Я.А., Сычев Д.А., Зырянов С.К., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Конради А.О., Драпкина О.М., Недогода С.В., Арутюнов Г.П., Карпов Ю.А., Кобалава Ж.Д., Орлова Я.А., Сычев Д.А., Зырянов С.К.</copyright-holder><copyright-holder xml:lang="en">Konradi A.O., Drapkina O.M., Nedogoda S.V., Arutyunov G.P., Karpov Y.A., Kobalava Z.D., Orlova Y.A., Sychev D.A., Zyryanov S.K.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/2244">https://htn.almazovcentre.ru/jour/article/view/2244</self-uri><abstract><p>1 декабря 2021 года в дистанционном режиме состоялся Совет экспертов по проблемам терапии артериальной гипертензии, ишемической болезни сердца, хронической сердечной недостаточности в период пандемии COVID-19, проведенный в целях изменений и адаптации текущих подходов амбулаторного лечения перечисленных нозологий в сложившейся эпидемиологической обстановке. В совещании приняли участие ведущие российские специалисты научно-медицинских исследовательских федеральных центров кардиологии и терапии.</p></abstract><trans-abstract xml:lang="en"><p>On December 1, 2021, a meeting of the Council of experts on the treatment of hypertension, coronary heart disease, and chronic heart failure during the COVID-19 pandemic was held remotely to adjust and adapt current approaches to outpatient treatment of the above pathologies under the current epidemiological situation. The meeting was attended by leading Russian specialists from federal medical research centers of cardiology and therapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>COVID-19</kwd><kwd>постковидный синдром</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>coronary artery disease</kwd><kwd>chronic heart failure</kwd><kwd>COVID-19</kwd><kwd>post-covid syndrome</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Совет экспертов прошел при поддержке компании MERCK.</funding-statement><funding-statement xml:lang="en">The Council of experts was supported by MERCK.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017</mixed-citation><mixed-citation xml:lang="en">Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Task Force for the management of COVID-19 of the European Society of Cardiology. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 — epidemiology, pathophysiology, and diagnosis. Eur Heart J. 2021;43(11):1033-1058. doi:10.1093/eurheartj/ehab696</mixed-citation><mixed-citation xml:lang="en">Task Force for the management of COVID-19 of the European Society of Cardiology. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 — epidemiology, pathophysiology, and diagnosis. Eur Heart J. 2021;43(11):1033-1058. doi:10.1093/eurheartj/ehab696</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Figliozzi S, Masci PG, Navid Ahmadi N, Tondi L, Koutli E, Aimo A et al. Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10): e13362. doi:10.1111/eci.13362</mixed-citation><mixed-citation xml:lang="en">Figliozzi S, Masci PG, Navid Ahmadi N, Tondi L, Koutli E, Aimo A et al. Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10): e13362. doi:10.1111/eci.13362</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215. doi:10.1371/journal.pone.0238215</mixed-citation><mixed-citation xml:lang="en">Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215. doi:10.1371/journal.pone.0238215</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-822. doi:10.1016/S22138587(20)30272-2</mixed-citation><mixed-citation xml:lang="en">Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-822. doi:10.1016/S22138587(20)30272-2</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128. doi:10.1111/obr.13128</mixed-citation><mixed-citation xml:lang="en">Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21(11):e13128. doi:10.1111/obr.13128</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Del Sole F, Farcomeni A, Loffredo L, Carneval R, Menichelli D, Vicario T et al. Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13378. doi:10.1111/eci.13378.</mixed-citation><mixed-citation xml:lang="en">Del Sole F, Farcomeni A, Loffredo L, Carneval R, Menichelli D, Vicario T et al. Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13378. doi:10.1111/eci.13378.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE et al. Factors associated with COVID-19-related death using Open SAFELY Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4</mixed-citation><mixed-citation xml:lang="en">Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE et al. Factors associated with COVID-19-related death using Open SAFELY Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wang T, Tang R, Ruan H, Chen R, Zhang Z, Sang L et al. China Medical Treatment Expert Group for COVID-19. Predictors of fatal outcomes among hospitalized COVID-19 patients with preexisting hypertension in China. Clin Respir J. 2021;15(8):915-924. doi:10.1111/crj.13382</mixed-citation><mixed-citation xml:lang="en">Wang T, Tang R, Ruan H, Chen R, Zhang Z, Sang L et al. China Medical Treatment Expert Group for COVID-19. Predictors of fatal outcomes among hospitalized COVID-19 patients with preexisting hypertension in China. Clin Respir J. 2021;15(8):915-924. doi:10.1111/crj.13382</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41(22):2058-2066. doi:10.1093/eurheartj/ehaa433</mixed-citation><mixed-citation xml:lang="en">Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41(22):2058-2066. doi:10.1093/eurheartj/ehaa433</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Martmez-Botfa P, Bernardo A, Acebes-Huerta A, Caro A, Leoz B, Martmez-Carballeira D et al. Clinical management of hypertension, inflammation and thrombosis in hospitalized COVID-19 patients: impact on survival and concerns. J Clin Med. 2021;10(5):1073. doi:10.3390/jcm10051073</mixed-citation><mixed-citation xml:lang="en">Martmez-Botfa P, Bernardo A, Acebes-Huerta A, Caro A, Leoz B, Martmez-Carballeira D et al. Clinical management of hypertension, inflammation and thrombosis in hospitalized COVID-19 patients: impact on survival and concerns. J Clin Med. 2021;10(5):1073. doi:10.3390/jcm10051073</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г. П., Тарловская Е. И., Арутюнов А. Г., Беленков Ю. Н., Конради А. О., Лопатин Ю. М. и др. Международный регистр “Анализ динамики Коморбидных заболеваний у пациентов, перенесших Инфицирование SARS-CoV-2” (AKTHB SARS-CoV-2): анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции. Российский кардиологический журнал. 2021;26(4):4470. doi: 10.15829/15604071-2021-4470.</mixed-citation><mixed-citation xml:lang="en">Arutyunov GP, Tarlovskaya EI, Arutyunov AG, Belenkov YN, Konradi AO, Lopatin YM et al. International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19. Russian Journal of Cardiology. 2021;26(4):4470. doi: 10.15829/1560-4071-2021-447. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol. 2019;19(8):517-532. doi:10.1038/s41577-019-0160-5</mixed-citation><mixed-citation xml:lang="en">Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol. 2019;19(8):517-532. doi:10.1038/s41577-019-0160-5</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS, Umber Saleem U, Arne Hansen A et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovasc Res. 2020;116(14):2207-2215. doi:10.1093/cvr/cvaa267</mixed-citation><mixed-citation xml:lang="en">Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS, Umber Saleem U, Arne Hansen A et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovasc Res. 2020;116(14):2207-2215. doi:10.1093/cvr/cvaa267</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bartoloni E, Perricone C, Cafaro G, Gerli R. Hypertension and SARS-CoV-2 infection: is inflammation the missing link? Cardiovasc Res. 2020;116(13):e193-e194. doi:10.1093/cvr/cvaa273</mixed-citation><mixed-citation xml:lang="en">Bartoloni E, Perricone C, Cafaro G, Gerli R. Hypertension and SARS-CoV-2 infection: is inflammation the missing link? Cardiovasc Res. 2020;116(13):e193-e194. doi:10.1093/cvr/cvaa273</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Smeda M, Chlopicki S. Endothelial barrier integrity in COVID-19-dependent hyperinflammation: does the protective facet of platelet function matter? Cardiovasc Res. 2020;116(10): e118-e121. doi:10.1093/cvr/cvaa190</mixed-citation><mixed-citation xml:lang="en">Smeda M, Chlopicki S. Endothelial barrier integrity in COVID-19-dependent hyperinflammation: does the protective facet of platelet function matter? Cardiovasc Res. 2020;116(10): e118-e121. doi:10.1093/cvr/cvaa190</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C, Wang Y, Li X, Re L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S01406736(20)30183-5</mixed-citation><mixed-citation xml:lang="en">Huang C, Wang Y, Li X, Re L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S01406736(20)30183-5</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE 2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097-1100.</mixed-citation><mixed-citation xml:lang="en">Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE 2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097-1100.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-818. doi:10.1001/jamacardio.2020.1017</mixed-citation><mixed-citation xml:lang="en">Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-818. doi:10.1001/jamacardio.2020.1017</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Meizlish ML, Pine AB, Goshua G, C-Hong C, Hanming Z, Jason B et al. Circulating markers of angiogenesis and endotheliopathy in COVID-19. Pulm Circ. 2020;10(4):2045894020966547. doi:10.1101/2020.06.29.20140376</mixed-citation><mixed-citation xml:lang="en">Meizlish ML, Pine AB, Goshua G, C-Hong C, Hanming Z, Jason B et al. Circulating markers of angiogenesis and endotheliopathy in COVID-19. Pulm Circ. 2020;10(4):2045894020966547. doi:10.1101/2020.06.29.20140376</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Invernizzi A, Schiuma M, Parrulli S, Torre A, Zicarelli F, Colombo V et al. Retinal vessels modifications in acute and post-COVID-19. Sci Rep. 2021;11(1):19373. doi:10.1038/s41598-021-98873-1</mixed-citation><mixed-citation xml:lang="en">Invernizzi A, Schiuma M, Parrulli S, Torre A, Zicarelli F, Colombo V et al. Retinal vessels modifications in acute and post-COVID-19. Sci Rep. 2021;11(1):19373. doi:10.1038/s41598-021-98873-1</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev. 2020;21(6):e13034. doi:10.1111/obr.13034</mixed-citation><mixed-citation xml:lang="en">Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev. 2020;21(6):e13034. doi:10.1111/obr.13034</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020;231(2):193-203.e1. doi:10.1016/j.jamcollsurg.2020.05.007</mixed-citation><mixed-citation xml:lang="en">Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020;231(2):193-203.e1. doi:10.1016/j.jamcollsurg.2020.05.007</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590. doi:10.1038/s41591-022-01689-3</mixed-citation><mixed-citation xml:lang="en">Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590. doi:10.1038/s41591-022-01689-3</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE 2. Science. 2020;367(6485):1444-1448. doi:10.1126/science.abb2762</mixed-citation><mixed-citation xml:lang="en">Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE 2. Science. 2020;367(6485):1444-1448. doi:10.1126/science.abb2762</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">South AM, Diz DI, Chappell MC. COVID-19, ACE 2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084-H1090. doi:10.1152/ajpheart.00217.2020</mixed-citation><mixed-citation xml:lang="en">South AM, Diz DI, Chappell MC. COVID-19, ACE 2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084-H1090. doi:10.1152/ajpheart.00217.2020</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Circulation. 2006;291(5):H2166-72. doi:10.1152/ajpheart.00061.2006.</mixed-citation><mixed-citation xml:lang="en">Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Circulation. 2006;291(5):H2166-72. doi:10.1152/ajpheart.00061.2006.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sommerstein R, Grani C. Rapid response: preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. Br Med J. 2020;368: m810. doi:10.1136/bmj.m810</mixed-citation><mixed-citation xml:lang="en">Sommerstein R, Grani C. Rapid response: preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. Br Med J. 2020;368: m810. doi:10.1136/bmj.m810</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81(5):537-540. doi:10.1002/ddr.21656</mixed-citation><mixed-citation xml:lang="en">Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81(5):537-540. doi:10.1002/ddr.21656</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9(3):275-284. doi:10.1016/S22132600(20)30558-0</mixed-citation><mixed-citation xml:lang="en">Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9(3):275-284. doi:10.1016/S22132600(20)30558-0</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Chen R, Yang J, Gao X, Ding X, Yang Y, Shen Y et al. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension. J Clin Hypertens (Greenwich). 2020;22(11):1974-1983. doi:10.1111/jch.14038</mixed-citation><mixed-citation xml:lang="en">Chen R, Yang J, Gao X, Ding X, Yang Y, Shen Y et al. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension. J Clin Hypertens (Greenwich). 2020;22(11):1974-1983. doi:10.1111/jch.14038</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Cremer S, Pilgram L, Berkowitsch A, Stecher M, Rieg S, Shumliakivska M et al. LEOSS study group (2021). Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. PLoS One. 2021;16(10):e0258684. doi:10.1371/journal.pone.0258684</mixed-citation><mixed-citation xml:lang="en">Cremer S, Pilgram L, Berkowitsch A, Stecher M, Rieg S, Shumliakivska M et al. LEOSS study group (2021). Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. PLoS One. 2021;16(10):e0258684. doi:10.1371/journal.pone.0258684</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Najmeddin F, Solhjoo M, Ashraf H, Salehi M, Rasooli F, Ghoghaei M et al. Effects of renin-angiotensin-aldosterone inhibitors on early outcomes of hypertensive COVID-19 patients: A Randomized Triple-Blind Clinical Trial. Am J Hypertens. 2021: hpab111. doi:10.1093/ajh/hpab111</mixed-citation><mixed-citation xml:lang="en">Najmeddin F, Solhjoo M, Ashraf H, Salehi M, Rasooli F, Ghoghaei M et al. Effects of renin-angiotensin-aldosterone inhibitors on early outcomes of hypertensive COVID-19 patients: A Randomized Triple-Blind Clinical Trial. Am J Hypertens. 2021: hpab111. doi:10.1093/ajh/hpab111</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Cremer S, Pilgram L, Berkowitsch A, Stecher M, Rieg S, Shumliakivska M et al. Discontinuation of antihypertensive medications on the outcome of hospitalized patients with severe acute respiratory syndrome-coronavirus 2. Hypertension. 2021;78(1):165-173. doi:10.1161/HYPERTENSIONAHA.121.17328</mixed-citation><mixed-citation xml:lang="en">Cremer S, Pilgram L, Berkowitsch A, Stecher M, Rieg S, Shumliakivska M et al. Discontinuation of antihypertensive medications on the outcome of hospitalized patients with severe acute respiratory syndrome-coronavirus 2. Hypertension. 2021;78(1):165-173. doi:10.1161/HYPERTENSIONAHA.121.17328</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Yan F, Huang F, Xu J, Yang P, Qin Y, Lv J et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discov. 2020;6(1):77. doi:10.1038/s41421-020-00221-6</mixed-citation><mixed-citation xml:lang="en">Yan F, Huang F, Xu J, Yang P, Qin Y, Lv J et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discov. 2020;6(1):77. doi:10.1038/s41421-020-00221-6</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Oh TK, Cho HW, Suh JW, Song IA. Incidence and mortality associated with cardiovascular medication among hypertensive COVID-19 patients in South Korea. Yonsei Med J. 2021;62(7):577-583. doi:10.3349/ymj.2021.62.7.577</mixed-citation><mixed-citation xml:lang="en">Oh TK, Cho HW, Suh JW, Song IA. Incidence and mortality associated with cardiovascular medication among hypertensive COVID-19 patients in South Korea. Yonsei Med J. 2021;62(7):577-583. doi:10.3349/ymj.2021.62.7.577</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Gao P, Wu W, Tian R, Yan X, Qian H, Guo F et al. Association between tachyarrhythmia and mortality in a cohort of critically ill patients with coronavirus disease 2019 (COVID-19). Ann Transl Med. 2021;9(10):883. doi:10.21037/atm-21-2282</mixed-citation><mixed-citation xml:lang="en">Gao P, Wu W, Tian R, Yan X, Qian H, Guo F et al. Association between tachyarrhythmia and mortality in a cohort of critically ill patients with coronavirus disease 2019 (COVID-19). Ann Transl Med. 2021;9(10):883. doi:10.21037/atm-21-2282</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Kow CS, Ramachandram DS, Hasan SS. Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis. Hypertens Res. 2021;45(2):360-363. doi:10.1038/s41440-021-00786-z</mixed-citation><mixed-citation xml:lang="en">Kow CS, Ramachandram DS, Hasan SS. Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis. Hypertens Res. 2021;45(2):360-363. doi:10.1038/s41440-021-00786-z</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев В. Ю., Орлова Я. А., Плисюк А. Г., Павликова Е. П., Мацкеплишвили С. Т., Акопян Ж. А. и др. Результаты открытого проспективного контролируемого сравнительного исследования по лечению новой коронавирусной инфекции (COVID-19): Бромгексин и Спиронолактон для лечения Корона-Вирусной Инфекции, Требующей госпитализации (БИСКВИТ). Кардиология. 2020;60(10):4-15.</mixed-citation><mixed-citation xml:lang="en">Mareev VYu, Orlova YaA, Plisyk AG, Pavlikova EP, Matskeplishvili ST, Akopyan ZA et al. Results of open-label non-randomized comparative clinical trial: “Bromhexine and Spironolactone for CoronаvirUs Infection requiring hospitalization (BISCUIT)”. Kardiologiia = Cardiology. 2020;60(10):4-15. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Kreutz R, Haas S, Holberg G, Lassen MR, Mantovani LG, Schmidt A et al. Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. Br J Clin Pharmacol. 2016;81(4):724-734. doi:10.1111/bcp.12836</mixed-citation><mixed-citation xml:lang="en">Kreutz R, Haas S, Holberg G, Lassen MR, Mantovani LG, Schmidt A et al. Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. Br J Clin Pharmacol. 2016;81(4):724-734. doi:10.1111/bcp.12836</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Holt A, Blanche P, Zareini B, Rasmussen PV, Strange JE, Rajan D et al. Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants. Heart. doi:10.1136/heartjnl-2021-319503</mixed-citation><mixed-citation xml:lang="en">Holt A, Blanche P, Zareini B, Rasmussen PV, Strange JE, Rajan D et al. Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants. Heart. doi:10.1136/heartjnl-2021-319503</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Голухова Е. З., Арсланбекова С. М., Сычев Д. А., Кузнецова Е. В. Особенности дозирования варфарина в условиях полифармакотерапии у пациентов после имплантации искусственных клапанов сердца. Креативная кардиология. 2013;1:58-65.</mixed-citation><mixed-citation xml:lang="en">Golukhova EZ, Arslanbekova SM, Sychev DA, Kuznetsova EV. Peculiarities of dosing of warfarin under conditions of polypharmacotherapy in patients after implantation of artificial heart valves. Creative Cardiology. 2013;1:58-65. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Chen W, Qian J, Fu J, Wu T, Lv M et al. Changes in the gut microbiota may affect the clinical efficacy of oral anticoagulants. Front Pharmacol. doi:10.3389/fphar.2022.860237</mixed-citation><mixed-citation xml:lang="en">Zhang J, Chen W, Qian J, Fu J, Wu T, Lv M et al. Changes in the gut microbiota may affect the clinical efficacy of oral anticoagulants. Front Pharmacol. doi:10.3389/fphar.2022.860237</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Ashcraft K, Moretz C, Schenning C, Rojahn S, Vines Tanudtanud K, Magoncia GO et al. Unmanaged pharmacogenomic and drug interaction risk associations with hospital length of stay among Medicare advantage members with COVID-19: A Retrospective Cohort Study. J Pers Med. 2021;11(11):1192. doi:10.3390/jpm11111192</mixed-citation><mixed-citation xml:lang="en">Ashcraft K, Moretz C, Schenning C, Rojahn S, Vines Tanudtanud K, Magoncia GO et al. Unmanaged pharmacogenomic and drug interaction risk associations with hospital length of stay among Medicare advantage members with COVID-19: A Retrospective Cohort Study. J Pers Med. 2021;11(11):1192. doi:10.3390/jpm11111192</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2 — care pathways, treatment, and follow-up. Eur Heart J. 2022;43(11):1059-1103. doi:10.1093/eurheartj/ehab697</mixed-citation><mixed-citation xml:lang="en">ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2 — care pathways, treatment, and follow-up. Eur Heart J. 2022;43(11):1059-1103. doi:10.1093/eurheartj/ehab697</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of postacute covid-19 in primary care. Br Med J. 2020;370:m3026. doi:10.1136/bmj.m3026</mixed-citation><mixed-citation xml:lang="en">Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of postacute covid-19 in primary care. Br Med J. 2020;370:m3026. doi:10.1136/bmj.m3026</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020;7(12):ofaa509. doi:10.1093/ofid/ofaa509</mixed-citation><mixed-citation xml:lang="en">Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis. 2020;7(12):ofaa509. doi:10.1093/ofid/ofaa509</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52(6):575-581. doi:10.1016/j.arcmed.2021.03.010</mixed-citation><mixed-citation xml:lang="en">Pavli A, Theodoridou M, Maltezou HC. Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021;52(6):575-581. doi:10.1016/j.arcmed.2021.03.010</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53(10):737-754. doi:10.1080/23744235.2021.1924397</mixed-citation><mixed-citation xml:lang="en">Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53(10):737-754. doi:10.1080/23744235.2021.1924397</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г. П., Тарловская Е. И., Арутюнов А. Г. от имени группы соавторов. Клинические особенности постковидного периода. Результаты международного регистра «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 (АКТИВ SARS-CoV-2)». Предварительные данные (6 месяцев наблюдения). Российский кардиологический журнал. 2021;26(10):4708. doi:10.15829/1560-4071-2021-4708</mixed-citation><mixed-citation xml:lang="en">Arutyunov GP, Tarlovskaya EI, Arutyunov AG on behalf of co-authors. Clinical features of post-COVID-19 period. Results of the international register “Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)”. Data from 6-month follow-up. Russian Journal of Cardiology. 2021; 26(10):4708. doi:10.15829/1560-4071-2021-4708. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Правительство Российской Федерации, Постановление от 18 июня 2021 г. № 927 «О внесении изменений в Программу государственных гарантий бесплатного оказания гражданам медицинской помощи на 2021 год и на плановый период 2022 и 2023 годов».</mixed-citation><mixed-citation xml:lang="en">Government of the Russian Federation, Decree of June 18, 2021 No. 927 “On amendments to the program of state guarantees of free medical care for citizens for 2021 and for the planning period of 2022 and 2023”. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Министерство Здравоохранения Российской Федерации, Приказ № 404н от 27.04.2021 «Об утверждении Порядка проведения профилактического медицинского осмотра и диспансеризации определенных групп взрослого населения».</mixed-citation><mixed-citation xml:lang="en">Ministry of health of the Russian Federation, Order No. 404n dated April 27, 2021 “On approval of the Procedure for conducting a preventive medical examination and medical examination of certain groups of the adult population”. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Министерство здравоохранения Российской Федерации, Приказ № 698н от 1.07.2021 «Об утверждении Порядка направления граждан на прохождения углубленной диспансеризации, включая категории граждан, проходящих углубленную диспансермммизацию в первоочередном порядке».</mixed-citation><mixed-citation xml:lang="en">Ministry of Health of the Russian Federation, Order No. 698n dated July 1, 2021 “On approval of the procedure for sending citizens to undergo in-depth medical examination, including categories of citizens undergoing in-depth medical examination as a matter of priority”. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Методическое пособие по проведению профилактического медицинского осмотра и диспансеризации определенных групп взрослого населения, углублённой" диспансеризации для граждан, перенесших новую коронавирусную инфекцию (COVID-19), Москва, 2021.</mixed-citation><mixed-citation xml:lang="en">Methodological guide for conducting preventive medical examination and medical examination of certain groups of the adult population, in-depth medical examination for citizens who have had a new coronavirus infection (COVID-19), Moscow, 2021. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Richter D, Guasti L, Koehler F, Squizzato A, Nistri S, Christodorescu R et al. Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice. ESC Heart Failure. 2021;8(5):3483-3494. doi:10.1002/ehf2.13466</mixed-citation><mixed-citation xml:lang="en">Richter D, Guasti L, Koehler F, Squizzato A, Nistri S, Christodorescu R et al. Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice. ESC Heart Failure. 2021;8(5):3483-3494. doi:10.1002/ehf2.13466</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
